Cancer Treatment with sHA 14-1 Reduces Side Effects by Increasing Programmed Cell Death
Bcl-2 Proteins Inhibit Apoptosis and Increase Drug Resistance to Cancer Treatment
An antagonist that targets anti-apoptotic Bcl-2 proteins has been developed for potential treatment of cancer. The Bcl-2 protein inhibits programmed cell death, or apoptosis, in cancer cells. In tumor cells, over expression of Bcl-2 has been correlated with the development of resistance to chemotherapy, radiotherapy, and hormone treatments. Because of drug resistance due to Bcl-2 proteins, cancer treatment dosages are increased to be more effective, but this leads to greater side effects.
|MN-IP Try and Buy|
|MN-IP Try and Buy deal terms are available upon request. Contact Raj Udupa for specific details.|
Bcl-2 Protein Antagonists Improve the Effectiveness of Cancer Treatment
HA 14-1 is a qualified antagonist against the anti-apoptotic Bcl-2 protein. The HA 14-1 molecule is an inhibitor that can sensitize cancer cells to cancer treatments, thereby lowering the effective dosage of anticancer agent and lowering the side effects. New analogs of HA 14-1 have demonstrated improved binding interaction with anti-apoptotic Bcl-2 proteins. One of these analogs, sHA 14-1, has greater stability compared to HA 14-1 but displays similar effectiveness on cancer cells. sHA 14-1 is insensitive to the drug resistance induced by anti-apoptotic Bcl-2 proteins in cancer cells. sHA 14-1 also synergizes the anti-cancer activities of both intrinsic and extrinsic apoptotic stimuli, increasing the potential of sHA 14-1 in cancer therapy.
BENEFITS OF Bcl-2 PROTEIN ANTAGONIST sHA 14-1 IN CANCER TREATMENT:
- Candidate for the treatment of drug-resistant cancers either as a monotherapy or in combination with current cancer treatments
- sHA 14-1 analog can sensitize cancers to cancer treatment as an antagonist to Bcl-2
- Reduces side effects by lowering the effective dosage of anticancer agent
Phase of Development HA14-1 analogues have been synthesized and tested for stability. In vitro binding assays have identified optimum structures and in vivo studies have been completed.